Management of Heart Failure from Rheumatic Heart Disease

Pharmacologic Management

• The European Society of Cardiology recommends beginning loop diuretics immediately if pulmonary congestion or peripheral edema is present to provide rapid symptomatic relief 1, 2
• Loop diuretics are essential when fluid overload manifests as pulmonary congestion or peripheral edema, resulting in rapid improvement of dyspnea and increased exercise tolerance in patients with heart failure 2
• The American Heart Association suggests that if glomerular filtration rate is less than 30 mL/min, thiazides should be avoided except when prescribed synergistically with loop diuretics in patients with heart failure 1
• For insufficient response to diuretics, the European Society of Cardiology recommends increasing the diuretic dose, combining loop diuretics with thiazides, or administering loop diuretics twice daily 1
• The European Society of Cardiology recommends starting ACE inhibitors as first-line therapy for left ventricular systolic dysfunction (ejection fraction <40-45%), even in asymptomatic patients with heart failure 2
• The American College of Cardiology suggests beginning with a low dose and uptitrating to target doses proven effective in large trials, not based on symptomatic improvement alone, when using ACE inhibitors in patients with heart failure 1, 2
• The European Society of Cardiology recommends reviewing and potentially reducing diuretics for 24 hours before initiating ACE inhibitors to avoid excessive diuresis in patients with heart failure 1
• The American Heart Association suggests monitoring blood pressure, renal function, and electrolytes 1-2 weeks after each dose increment, at 3 months, and subsequently at 6-month intervals when using ACE inhibitors in patients with heart failure 1, 2
• If renal function deteriorates substantially, the European Society of Cardiology recommends stopping ACE inhibitor treatment in patients with heart failure 1
• The American College of Cardiology recommends adding beta-blockers (bisoprolol, carvedilol, or metoprolol XL/CR) to ACE inhibitors and diuretics for all patients with stable heart failure and reduced ejection fraction in NYHA class II-IV 1
• The European Society of Cardiology suggests adding spironolactone for advanced heart failure (NYHA class III-IV) in addition to ACE inhibitors and diuretics to improve survival and morbidity in patients with heart failure 1
• The American Heart Association recommends avoiding non-steroidal anti-inflammatory drugs (NSAIDs) as they interfere with ACE inhibitor efficacy in patients with heart failure 1
• The European Society of Cardiology suggests avoiding potassium-sparing diuretics during ACE inhibitor initiation in patients with heart failure 1
• The American College of Cardiology recommends avoiding calcium channel blockers with negative inotropic effects (non-dihydropyridines) in patients with ejection fraction less than 50% 3

Alternative Therapies

• The European Society of Cardiology recommends substituting angiotensin receptor blockers (ARBs) if ACE inhibitors cause intolerable cough or angioedema in patients with heart failure 2

Management of Congestive Heart Failure Secondary to Rheumatic Heart Disease

Initial Management

• The American College of Cardiology recommends initiating standard guideline-directed medical therapy for heart failure and mandatory secondary prophylaxis with benzathine penicillin G 1.2 million units IM every 4 weeks to prevent recurrent rheumatic fever in patients with congestive heart failure secondary to rheumatic heart disease 4, 5

Diagnostic Workup

• The American Heart Association suggests performing a structured evaluation, including volume status assessment, functional capacity, laboratory evaluation, cardiac imaging, and 12-lead ECG and chest radiograph to identify arrhythmias, conduction abnormalities, and pulmonary congestion in patients with congestive heart failure secondary to rheumatic heart disease 6

Pharmacologic Management

• The American College of Cardiology recommends starting loop diuretics immediately if pulmonary congestion or peripheral edema is present, and implementing guideline-directed medical therapy for left ventricular systolic dysfunction, including ACE inhibitors, beta-blockers, aldosterone antagonists, and sacubitril/valsartan in patients with congestive heart failure secondary to rheumatic heart disease 4, 5, 7, 8
• The American Heart Association suggests using digoxin for symptom control, particularly beneficial if atrial fibrillation is present, and hydralazine/isosorbide dinitrate as alternative vasodilator therapy if ACE inhibitors and ARBs are contraindicated 9

Atrial Fibrillation Management

• The American College of Cardiology recommends rate control using beta-blockers or digoxin, and anticoagulation with warfarin in patients with rheumatic heart disease and atrial fibrillation 9, 10

Mandatory Secondary Prophylaxis

• The American Heart Association recommends lifelong antibiotic prophylaxis with benzathine penicillin G 1.2 million units IM every 4 weeks to prevent recurrent acute rheumatic fever in patients with rheumatic heart disease 11, 4, 7, 8, 5

Additional Preventive Measures

• The American College of Cardiology recommends infective endocarditis prophylaxis, optimal oral health maintenance, and influenza and pneumococcal vaccinations to reduce the risk of complications in patients with rheumatic heart disease 11, 4, 8, 5

Monitoring and Follow-Up

• The American Heart Association suggests regular echocardiographic surveillance, every 6-12 months for severe disease, every 1-2 years for moderate disease, and every 3-5 years for mild disease, to assess for disease progression in patients with rheumatic heart disease 5, 9

Entresto Initiation Guidelines for Symptomatic Heart Failure Patients

Patient Eligibility and Initiation Criteria

• The American College of Cardiology recommends starting Entresto immediately in patients with LVEF ≤40% who remain symptomatic (NYHA class II-III) despite at least 3 months of optimal therapy with ACE inhibitors or ARBs, beta-blockers, and mineralocorticoid receptor antagonists 12
• Patients with LVEF ≤40% documented on echocardiography or other cardiac imaging are eligible for Entresto initiation, according to the American Heart Association 13, 12
• A minimum of 3 months of ACE inhibitor or ARB therapy at guideline-directed doses is required before initiating Entresto, as recommended by the American College of Cardiology 12
• Persistent symptoms (NYHA class II or III) despite optimal medical therapy are an indication for Entresto initiation, according to the American Heart Association 12
• Concurrent therapy with beta-blockers and mineralocorticoid receptor antagonists must be established before starting Entresto, as recommended by the American College of Cardiology 13

Dosing and Titration

• The American College of Cardiology recommends targeting at least 50% of the maximum dose (49 mg/51 mg twice daily minimum) for optimal benefit 14
• Uptitration to the target maintenance dose of 97 mg/103 mg twice daily should be done every 2-4 weeks, according to the Journal of the American College of Cardiology 14

Evidence Supporting Entresto Use

• The American College of Cardiology reports a 20% reduction in the composite endpoint of cardiovascular death or heart failure hospitalization compared to enalapril with Entresto use 12
• The American Heart Association guidelines establish Entresto as preferred over ACE inhibitors/ARBs for symptomatic HFrEF patients, based on evidence from Circulation 13, 12